Medipure’s R&D team has committed to developing innovative therapeutics for use in pain management and oncology, as well as the treatment of anxiety, rheumatoid arthritis, and dermatitis. Using green technology, Medipure’s physician and patient driven pharmaceutical R&D approach will create specific R&D-based prescription therapeutics dedicated to improving the quality of life of patients.

At present, physicians and regulators have raised significant concerns regarding the prescription of first-line therapies. These concerns relate primarily to dose, safety, and efficacy. At Medipure, our capacity in research will ensure our products are designed for an optimized, therapeutic effect for a given illness, all while minimizing the negative side effects of first-line therapeutics. These products will strive to establish well-defined, measurable standards of dosage, delivery, safety, and efficacy. 

Medipure’s R&D Centre (MRC) will feature all the tools necessary to perform cutting-edge preclinical (in vitro and in vivo) studies using proprietary formulations. This preclinical capacity will allow us to identify the molecular mechanisms by which our therapeutics exert their effects, and more importantly, determine the safety, dosage, efficacy, and pharmaco/toxico kinetics/dynamics profiles to ensure successful and comprehensive clinical trials. The MCRC will also house a full phytochemistry R&D lab in which to analyze, extract, purify, and formulate APIs and Phytochemicals into medicines.

Scientists, physicians, and technology are the driving forces behind our ability to produce purified molecules from carefully selected strains. Our in-house "plant-to-pill" capacity will allow us to refine phytochemicals to pharmaceutical-grade prescriptions.